Search results
Results from the WOW.Com Content Network
Humira created tremendous shoes to fill, but AbbVie may have done it. Analysts are calling for approximately $63.5 billion in revenue in 2025, the first time AbbVie would surpass $60 billion in sales.
Let's illustrate: Since 2013, AbbVie's stock price has lagged the pace of the Nasdaq Composite. ... Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors.
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development, over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
For reference, AbbVie's trailing 12-month revenue was $55.3 billion, so the growth of Skyrizi and Rinvoq represents a major addition to the top line that'll likely drive the stock upwards for ...
AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what makes AbbVie a long-term buy-and-hold dividend gold mine.
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t ...
The drugmaker has convincingly laid to rest the biggest threat to its top line.